Category Archives: Public research

Pharmaceutical corporations need to stop free-riding on publicly-funded research

Posted on June 1, 2018 by donttradeourlivesaway

by Jason Cone, The Hill The White House Council of Economic Advisers recently announced a strategy to curb high drug prices: force “free riding” countries abroad to pay more and watch the prices go down in America. That’s not how … Continue reading →

Posted in Public funded research, Public research, R&D, Uncategorized | Leave a comment

Patent Law Holds Back Science

Posted on March 25, 2016 by donttradeourlivesaway

Bloomberg View; March 23, 2016. By Noah Smith. One of the biggest stories in science right now is the fight over the Crispr patents. Crispr is a gene editing technique that promises to allow previously unthinkable feats of bio-engineering. It was … Continue reading →

Posted in Bayh Dole Act, Patents, Public research, Uncategorized | Leave a comment

G-Finder Report: Ebola Distracted R&D Funding For Neglected Diseases; Public Funding At Low

Posted on December 14, 2015 by donttradeourlivesaway

IP Watch; December 8, 2015. A newly issued report provides the “first ever” picture of global investment in Ebola research and development. The report found that investment in Ebola might have come at the expense of other funding to develop drugs, … Continue reading →

Posted in Ebola, Innovation, Neglected Diseases, Public research | Leave a comment

The Medicines Patent Pool Signs a Collaborative Agreement with the University of Liverpool to Develop HIV Nanomedicines

Posted on December 8, 2015 by donttradeourlivesaway

Medicines Patent Pool; December 1, 2015. Geneva – The Medicines Patent Pool (MPP) today announced a collaboration with the University of Liverpool and a licence for the university’s Solid Drug Nanoparticle (SDN) technology to accelerate the development of WHO-recommended antiretrovirals as nanomedicines. The … Continue reading →

Posted in HIV/Aids, Medicine Patent Pool, Public research | Leave a comment

Big Pharma owes a debt to society

Posted on November 26, 2015 by donttradeourlivesaway

Providence Journal, November 3, 2015. By Mariana Mazzucato. When Martin Shkreli of Turing Pharmaceuticals raised the price for Daraprim by 5,455 percent, he put drug pricing on the agenda for the leading 2016 presidential candidates. Bernie Sanders is reported to have … Continue reading →

Posted in Big Pharma myths, Innovation, Me-too-drugs, Pricing, Public research | Leave a comment